TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial

No adverse events related to TCB008 have occurred Evidence of stable disease following TCB008 infusionEDINBURGH, Scotland, Feb. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has concluded dosing of Cohort A patients in the ACHIEVE Phase 2B UK clinical trial.The available data show a favorable safety ...